Paper Details

  1. Home
  2. Paper Details

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

Author: MarianoN, MilellaM, MonnoL, MoschettaR, PastoreG, PolliceL, SantantonioT

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 18 patients with chronic hepatitis B found that interferon alpha treatment (5 MU/m2 three times a week for 6 months) effectively reduced hepatitis B virus (HBV) DNA levels and improved liver function. However, after stopping treatment, the virus reappeared in 89% of patients within 17 months. The study concluded that interferon alpha provides a temporary benefit for chronic hepatitis B and that a 6-month treatment regimen is insufficient to eliminate the virus from the liver cells.
Paper Details　
Original Abstract of the Article :
Eighteen heterosexual HBsAg carriers with anti-HBe- and HBV-DNA-positive chronic hepatitis B (CHB) were randomly assigned to receive human lymphoblastoid interferon (ly-IFN) at a dose of 5 MU/m2 i.m. three times a week for 6 months (ten cases) or no treatment (eight cases). All patients were followe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0168-8278(92)90161-h

データ提供：米国国立医学図書館（NLM）

Interferon: A Transient Oasis in the Desert of Chronic Hepatitis B

Chronic hepatitis B (CHB) is a serious liver infection that requires long-term treatment. This study investigates the effectiveness of lymphoblastoid interferon (ly-IFN) in treating patients with anti-HBe-positive CHB, a specific type of CHB characterized by the presence of antibodies against HBe antigen and HBV-DNA in the serum.

The study found that ly-IFN temporarily reduced HBV-DNA levels and improved liver function in most patients during treatment. However, the majority of patients experienced a relapse after treatment discontinuation, with HBV-DNA reappearing and liver disease activity reactivating. These findings suggest that ly-IFN may not be a long-term solution for anti-HBe-positive CHB.

The Shifting Sands of Chronic Hepatitis B: A Quest for Durable Treatment

The study highlights the challenges of treating CHB, as finding a durable solution remains an ongoing quest. The temporary effectiveness of ly-IFN underlines the need for alternative therapies or strategies that can achieve sustained viral suppression.

Navigating the Desert of Hepatitis B: A Search for Effective Treatment

This study reminds us that the treatment of CHB is a complex journey through the desert of medicine. Finding a treatment that can provide lasting relief remains a priority. The study's findings suggest that new approaches are needed to overcome the challenges of viral persistence and reactivation.

Dr.Camel's Conclusion

The treatment of chronic hepatitis B is a challenging journey through a vast and unforgiving desert. This study highlights the limitations of ly-IFN as a long-term solution. It's like finding a temporary oasis that provides some relief, but ultimately doesn't offer a permanent escape from the harsh realities of this disease. The search for a durable treatment continues, and new therapies are needed to conquer this formidable foe.

Date :
  1. Date Completed 1992-09-15
  2. Date Revised 2019-08-17
Further Info :

Pubmed ID

1500686

DOI: Digital Object Identifier

10.1016/0168-8278(92)90161-h

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.